Evidence map›Paper›PMID 34528858›Full record

ArticleBioengineered2021

Quercetin alleviates chronic renal failure by targeting the PI3k/Akt pathway.

Haitao Tu, Duanhua Ma, Yuanyuan Luo, Shuifu Tang, Ying Li, Gangyi Chen, Liangliang Wang, Zhengkun Hou, Chuangpeng Shen, Huan Lu and 2 more

Open access · goldAbstract read
In one paragraph

Article in Bioengineered, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 68 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Molecular medicine reports · 2024
    Article
  18. Article
  19. The role of PI3K/Akt signaling pathway in chronic kidney disease.International urology and nephrology · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Haitao TuDivision of Nephrology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, China.
Duanhua MaScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, China.
Yuanyuan LuoDepartment of Intensive Care Unit, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Shuifu TangDivision of Nephrology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, China.
Ying LiDivision of Nephrology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.
Gangyi ChenDivision of Nephrology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, China.
Liangliang WangDivision of Nephrology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, China.
Zhengkun HouDepartment of Gastroenterology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Chuangpeng ShenDepartment of Endocrinology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Huan LuDivision of Nephrology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, China.
Xun ZhuangDepartment of Rehabilitation Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Liangyou ZhangDivision of Nephrology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong, Guangzhou, China.
First Affiliated Hospital of Guangzhou University of Chinese Medicine · CNFirst People's Hospital of Chongqing · CNGuangzhou University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic renal failure (CRF) threatens human health greatly and attracts worldwide concerns of health professionals in the public health sector. In our preliminary study, we found that Compound capsule (Shengqing Jiangzhuo Capsule, SQJZJN) had a significant therapeutic effect on CRF. Quercetin is one of the main components of this Compound capsule. In this study, we investigated the effect of Quercetin monomer on CRF and the regulation of PI3k/Akt pathway. Network pharmacology analysis methods were employed to analyze the SQJZJN/Quercetin/PIK3R1 network relationships. In this study, a CRF rat model was prepared using the gavage adenine solution method and detected the indicators of Creatinine (Cr), Blood Urea Nitrogen (BUN), and Uric Acid (UA). After treating the rat model with Quercetin and PIK3R1-interfering lentivirus, respectively, we observed the changes on the histological morphology of the kidney and detected apoptosis using TUNEL staining. Gene and protein expression associated with renal function were detected using qPCR, WB and immunofluorescence. Quercetin was identified as the main ingredient of SQJZJN by the network pharmacological screening and Quercetin at 1.5 and 3 g/(kg.d) concentrations could effectively alleviate the CRF symptoms, reduce the levels of Cr, BUN, and UA, and markedly inhibit cell apoptosis demonstrated by the intragastric administration. Furthermore, the protein expression of p-PI3K, p-AKT, NLRP3, caspase1, AQP1, and AQP2 in all groups was detected by immunofluorescence and western blot assays, indicating that Quercetin could reduce the expression of NLRP3, caspase1, p-PI3k, and p-Akt, and increase the expression of AQP1 and AQP2 in the renal tissues of CRF rats. Being labeled with biotin and incubated with the total protein extracted from kidney tissues, Quercetin could bind to PIK3R1. Following the PIK3R1 interference lentivirus was injected into the CRF model rats by tail vein, the CRF symptoms were effectively alleviated in the PIK3R1 interference group, consistent with the effect of Quercetin. Taken together, Quercetin, a major component of SQJZJN, might minimize renal fibrosis and apoptosis in CRF rats by inhibiting the PI3k/Akt pathway through targeting PIK3R1. By regulating AQP1 and AQP2, both water retention and toxin accumulation were reduced.

Indexed as

Kidney Failure, ChronicPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktAnimalsAquaporinsClass Ia Phosphatidylinositol 3-KinaseDisease Models, AnimalKidneyMaleNetwork PharmacologyQuercetinRatsRats, Sprague-DawleyAquaporinsClass Ia Phosphatidylinositol 3-KinasePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktQuercetinCRFpi3k/aktpik3r1quercetin

Identifiers

PMID34528858
PMCPMC8806539
OpenAlexW3200285959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.